Growth during treatment of familial hypercholesterolemia
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Growth during treatment of familial hypercholesterolemia. / Hansen, Dorthe; Michaelsen, Kim Fleischer; Skovby, Flemming.
In: Acta Pædiatrica, Vol. 81, No. 12, 1992, p. 1023-1025.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Growth during treatment of familial hypercholesterolemia
AU - Hansen, Dorthe
AU - Michaelsen, Kim Fleischer
AU - Skovby, Flemming
PY - 1992
Y1 - 1992
N2 - Treatment of hypercholesterolemic children with restriction of dietary saturated fat may result in an inadequate supply of energy for normal somatic growth. We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid‐binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5.5 years + 3.5 years in 17 patients treated with diet followed by diet and colestipol. Statistically significant reductions in serum total cholesterol were obtained in both groups. The SD scores for both height/age and weight/age decreased by approximately 0.4 during dietary treatment (p<0.05), but were not affected by treatment with colestipol. These results document the risk of growth retardation during dietary treatment of children with familial hypercholesterolemia.
AB - Treatment of hypercholesterolemic children with restriction of dietary saturated fat may result in an inadequate supply of energy for normal somatic growth. We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid‐binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5.5 years + 3.5 years in 17 patients treated with diet followed by diet and colestipol. Statistically significant reductions in serum total cholesterol were obtained in both groups. The SD scores for both height/age and weight/age decreased by approximately 0.4 during dietary treatment (p<0.05), but were not affected by treatment with colestipol. These results document the risk of growth retardation during dietary treatment of children with familial hypercholesterolemia.
KW - Cholesterol
KW - Colestipol
KW - Diet
KW - Familial hypercholesterolemia
KW - Growth
UR - http://www.scopus.com/inward/record.url?scp=0027082668&partnerID=8YFLogxK
U2 - 10.1111/j.1651-2227.1992.tb12167.x
DO - 10.1111/j.1651-2227.1992.tb12167.x
M3 - Journal article
C2 - 1290846
AN - SCOPUS:0027082668
VL - 81
SP - 1023
EP - 1025
JO - Acta Paediatrica
JF - Acta Paediatrica
SN - 0803-5253
IS - 12
ER -
ID: 258034733